Minimal hepatic encephalopathy is associated with falls

American Journal of Gastroenterology

Volumn 106, Issue 3, 2011, Pages 476-482

  Román, Eva ^a,b   Córdoba, Joan ^a,b,c   Torrens, Maria ^c   Torras, Xavier ^a,b   Villanueva, Cndid ^a,b   Vargas, Víctor ^a,b,c   Guarner, Carlos ^a,b   Soriano, Germán ^a,b  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; SEDATIVE AGENT; SODIUM;

ADULT; AGE; AGED; ARTICLE; CONTROLLED STUDY; CRITICAL FLICKER FUSION; FALLING; FEMALE; HEALTH CARE UTILIZATION; HEPATIC ENCEPHALOPATHY; HOSPITALIZATION; HUMAN; INCIDENCE; INJURY SEVERITY; LIVER CIRRHOSIS; LIVER FAILURE; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MINIMAL HEPATIC ENCEPHALOPATHY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; SODIUM BLOOD LEVEL; TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT;

ACCIDENTAL FALLS; AGED; AUTOMOBILE DRIVING; CASE-CONTROL STUDIES; FEMALE; HEPATIC ENCEPHALOPATHY; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; PSYCHOMETRICS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SPAIN;

EID: 79952361622     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2010.413     Document Type: Article

References (46)

1. Ortiz M, Jacas C, C ó rdoba J. Minimal hepatic encephalopathy: diagnosis, clinical significance and recommendations. J Hepatol 2005;42:S45-53. (Pubitemid 40364603)
2. Romero-G ó mez M, C ó rdoba J, Rodrigo M et al Value of the critical flicker frequency in patients with minimal hepatic encephalopathy. Hepatology 2007 45 879-85. (Pubitemid 46631556)
3. Bajaj JS. Minimal hepatic encephalopathy matters in daily life. World J Gastroenterol 2008;14:3609-15.
4. Kircheis G, Wettstein M, Timmermann L et al. Critical flicker frequency for quantification of low-grade hepatic encephalopathy. Hepatology 2002;35:357-66. (Pubitemid 34106375)
5. Bajaj JS, Hafeezullah M, Franco J et al. Inhibitory control test for the diagnosis of minimal hepatic encephalopathy. Gastroenterology 2008;135:1591-600.
6. Weissenborn K, Ennen JC, Schomerus H et al. Neuropsychological characterization of hepatic encephalopathy. J Hepatol 2001;34:768-73. (Pubitemid 32488796)
7. Schiff S, Vallesi A, Mapelli D et al. Impairment of response inhibition precedes motor alteration in the early stage of liver cirrhosis: a behavioral and electrophysiological study. Metab Brain Dis 2005;20:381-92. (Pubitemid 43029810)
8. Romero-Gómez M, Grande L, Camacho I. Prognostic value of altered oral glutamine challenge in patients with minimal hepatic encephalopathy. Hepatology 2004;39:939-43. (Pubitemid 38428932)
9. Les I, Doval E, Flavi à M et al. Quality of life in cirrhosis is related to potentially treatable factors. Eur J Gastroenterol Hepatol 2010;22:221-7.
10. Groeneweg M, Moerland W, Quero JC et al. Screening of subclinical hepatic encephalopathy. J Hepatol 2000;32:748-53. (Pubitemid 30262734)
11. Bajaj JS, Hafeezullah M, Hoffmann RG et al. Minimal hepatic encephalopathy: a vehicle for accidents and traffic violations. Am J Gastroenterol 2007;102:1903-9. (Pubitemid 47301540)
12. Bajaj JS, Hafeezullah M, Hoffmann RG et al. Navigation skill impairment: another dimension of the driving difficulties in minimal hepatic encephalopathy . Hepatology 2008;47:596-604. (Pubitemid 351280728)
13. Bajaj JS, Saeian K, Schubert CM et al. Minimal hepatic encephalopathy is associated with motor vehicle crashes: the reality beyond the driving test. Hepatology 2009;50:1175-83.
14. Wein C, Koch H, Popp B et al. Minimal hepatic encephalopathy impairs fitness to drive. Hepatology 2004;39:739-45. (Pubitemid 38337653)
15. Córdoba J, Lucke R. Driving under the influence of minimal hepatic encephalopathy. Hepatology 2004 39 599-601. (Pubitemid 38337637)
16. Schomerus H, Hamster W, Blunck H et al. Latent portosystemic encephalopathy. I Nature of cerebral functional defects and their effect on fitness to drive. Dig Dis Sci 1981;26:622-30. (Pubitemid 11093388)
17. Collier J. Bone disorders in chronic liver disease. Hepatology 2007;46:1271-8. (Pubitemid 350144791)
18. Cohen SM, Te HS, Levitsky J. Operative risk of total hip and knee arthroplasty in cirrhotic patients. J Arthroplasty 2005;20:460-6. (Pubitemid 40804451)
19. Gua ñ abens N, Par é s A, Ros I et al Severity of cholestasis and advanced histological stage but no menopausal status are the major risk factors for osteoporosis in primary biliary cirrhosis. J Hepatol 2005 42 573-7. (Pubitemid 40342938)
20. Diamond T, Stiel D, Lunzer M et al. Osteoporosis and skeletal fractures in chronic liver disease. Gut 1990;31:82-7. (Pubitemid 20037985)
21. Ström O, Borgstrom F, Zethraeus N et al Long-term cost and effect on quality of life of osteoporosis-related fractures in Sweden. Acta Orthop 2008 79 269-80. (Pubitemid 351878360)
22. Pike C, Birnbaum HG, Schiller M et al. Direct and indirect costs of nonvertebral fracture patients with osteoporosis in the US. Pharmacoeconomics 2010;28:395-409.
23. Romero-Gómez M, Córdoba J, Jover R et al. Red Nacional de Investigaci ó n de Encefalopat í a Hep á tica. Normality tables in the Spanish population for psychometric tests used in the diagnosis of minimal hepatic encephalopathy. Med Clin (Barc) 2006;127:246-9. (Pubitemid 44343355)
24. Kerse N, Flicker L, Pfaff JJ et al. Falls, depression and antidepressants in later life: a large primary care appraisal. PLoS One 2008;3:e2423.
25. Falls. Geneva. World Health Organization. Violence and injury prevention and disability department (. http://www.who.int/violence-injury-prevention/ other-injury/falls/en/index.html. Accessed 20 March 2008).
26. Fischer ID, Krauss MJ, Dunagan WC et al. Patterns and predictors of inpatient falls and fall-related injuries in a large academic hospital. Infect Control Hosp Epidemiol 2005;26:822-7. (Pubitemid 41502515)
27. Gates S, Lamb SE, Fisher JD et al. Multifactorial assessment and targeted intervention for preventing falls and injuries among older people in community and emergency care settings: systematic review and meta-analysis. BMJ 2008;336:130-3. (Pubitemid 351211964)
28. Nordin E, Lindel ö f N, Rosendahl E et al. Prognostic validity of the Timed Up-and-Go test, a modified Get-Up-and-Go test, staff 's global judgement and fall history in evaluating fall risk in residential care facilities. Age Ageing 2008;37:442-8. (Pubitemid 351965890)
29. Medow MS, Stewart JM, Sanyal S et al. Pathophysiology, diagnosis, and treatment of orthostatic hypotension and vasovagal syncope. Cardiol Rev 2008;16:4-20. (Pubitemid 350308700)
30. Quero JC, Hartmann IJ, Meulstee J et al. The diagnosis of subclinical hepatic encephalopathy in patients with cirrhosis using neuropsychological tests and automated electroencephalogram analysis. Hepatology 1996;24:556-60. (Pubitemid 26295997)
31. Amodio P, Del Piccolo F, Pettenò E et al. Prevalence and prognostic value of quantified electroencephalogram (EEG) alterations in cirrhotic patients. J Hepatol 2001;35:37-45. (Pubitemid 32646222)
32. Close J, Ellis M, Hooper R et al. Prevention of falls in the elderly trial (PROFET): a randomised controlled trial. Lancet 1999;353:93-7. (Pubitemid 29088077)
33. Peeters G, Van Schoor NM, Lips P. Fall risk: the clinical relevance of falls and how to integrate fall risk with fracture risk. Best Pract Res Clin Rheumatol 2009;23:797-804.
34. Vestergaard P. Fracture risks of antidepressants. Expert Rev Neurother 2009;9:137-41.
35. Thapa PB, Gideon P, Cost TW et al. Antidepressants and the risk of falls among nursing home residents. N Engl J Med 1998;339:875-82. (Pubitemid 28446845)
36. Richards JB, Papaioannou A, Adachi JD et al. Effect of selective serotonin reuptake inhibitors on the risk of fracture. Arch Intern Med 2007;167:188-94. (Pubitemid 46148067)
37. Lozeva V, Montgomery JA, Tuomisto L et al. Increased brain serotonin turnover correlates with the degree of shunting and hyperammonemia in rats following variable portal vein stenosis. J Hepatol 2004;40:742-8. (Pubitemid 38507353)
38. Schlatter C, Egger SS, Tchambaz L et al. Pharmacokinetic changes of psychotropic drugs in patients with liver disease: implications for dose adaptation. Drug Saf 2009;32:561-78.
39. Bass NM, Mullen KD, Sanyal A et al. Rifaximin treatment in hepatic encephalopathy. N Engl J Med 2010;362:1071-81.
40. Prasad S, Dhiman RK, Duseja A et al. Lactulose improves cognitive functions and health-related quality of life in patients with cirrhosis who have minimal hepatic encephalopathy. Hepatology 2007;45:549-59. (Pubitemid 46450607)
41. Liu Q, Ping Duan Z, Kang Ha D et al. Synbiotic modulation of gut flora: effect on minimal hepatic encephalopathy in patients with cirrhosis. Hepatology 2004;39:1441-9. (Pubitemid 38569067)
42. Sharma BC, Sharma P, Agrawal A et al. Secondary prophylaxis of hepatic encephalopathy: an open-label randomized controlled trial of lactulose versus placebo. Gastroenterology 2009;137:885-91.
43. Tinetti E, Kumar C. The patient who falls: " It's always a trade-off ". JAMA 2010;303:258-66.
44. Gillespie LD, Gillespie WJ, Robertson MC et al. Interventions for preventing falls in elderly people. Cochrane Database Syst Rev 2009 (2): CD000340; doi: 10.1002/14651858.CD000340.pub2.
45. Jover R, Company L, Guti é rrez A et al. Minimal hepatic encephalopathy and extrapyramidal signs in patients with cirrhosis. Am J Gastroenterol 2003;98:1599-604. (Pubitemid 36875354)
46. Bajaj JS, Schubert CM, Heuman DM et al. Persistence of cognitive impairment aft er resolution of overt hepatic encephalopathy. Gastroenterology 2010;138:2332-40.